Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of...
Transcript of Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of...
![Page 1: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/1.jpg)
Treatment of Tuberculosis “Therapeutic Drug Monitoring”
2nd European Advanced Course in Clinical Tuberculosis
Dr. JWC Alffenaar, clinical pharmacologist
Dept Clinical Pharmacy & Pharmacology
University Medical Center Groningen
![Page 2: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/2.jpg)
Overview
• Background & definitions
• Why & How
• Clinical case presentation
• Tools for TDM
• TDM in programmatic TB treatment
![Page 3: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/3.jpg)
Clinical Pharmacokinetics is about all the factors that determine variability in the concentration of the drug in time
Therapeutic Drug Monitoring is about treatment optimization based on the drug concentration and clinical characteristics and condition of the patient
Time post dose
Se
rum
co
nce
ntr
atio
n
MIC
![Page 4: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/4.jpg)
Therapeutic Window
Drug concentration
Effe
ct
Toxi
city
![Page 5: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/5.jpg)
Time post dose
Seru
m c
once
ntr
ation
MIC
![Page 6: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/6.jpg)
“1% of tuberculosis patients with perfect adherence would still develop MDR-tuberculosis due to
pharmacokinetic variability alone”
“Low rifampin and isoniazid peak and AUC concentrations preceded all cases of acquired drug
resistance”.
“Poor outcomes were observed in patients with at least 1 drug concentration below the target (OR = 14.14).”
Srivastava JID 2012, Pasipanodya JID 2013
Does drug concentration matter?
![Page 7: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/7.jpg)
• Thirteen randomized studies – 1631 rapid acetylators
– 1751 slow acetylators
• Rapid acetylators were more likely than slow acetylators to have: – microbiological failure (RR, 2.0; CI, 1.5–2.7)
– aquired drug resistance (RR, 2.0; CI, 1.1–3.4)
– relapse (RR, 1.3; CI, .9–2.0)
INH concentration related failure
Pasipanodya CID 2012
Higher failure rates were encountered even in
drug regimens comprising >3 antibiotics.
![Page 8: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/8.jpg)
How do we optimize treatment using TDM?
![Page 9: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/9.jpg)
• Correlation:
– drug concentration and therapeutic response
– drug concentration and toxicity
• Inter and intra patient PK variability
Drug concentration => Effect?
![Page 10: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/10.jpg)
Time post dose
Se
rum
co
nce
ntr
atio
n
MIC
PK/PD parameters
Cmax
AUC
AUC/MIC ratio Cmax/MIC ratio T > MIC
0 24h
Absorption / Distribution / Clearance
Cmin
![Page 11: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/11.jpg)
• Target AUC/MIC ratio > 100 [1-3]
Moxifloxacin
1 Nuermberger EJCMID 2004, 2 Gumbo JID 2004, 3 Shandil AAC 2003
Ratio 25
Ratio 100
![Page 12: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/12.jpg)
Moxifloxacin
Pranger ERJ 2010
• 7-fold diff. in AUC • 8-fold diff in MIC (0.125-1 mg/L) • AUC/MIC ratio: 82 (21–320)
![Page 13: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/13.jpg)
Time post dose (h)
0 5 10 15 20 25 30
Moxiflo
xa
cin
co
nce
ntr
atio
n (
mg
/L)
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
day 6
day 54
Moxifloxacin; influence of disease?
• Female, 42 yrs from Indonesia with MDR-TB
– 34kg
– HIV positive
• Routine TDM:
– Day 7 (●)
– After 7 weeks (o)
![Page 14: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/14.jpg)
• Male, 27 yrs from Russia
• HIV positive
• DST: normal sensitive
• Standard treatment
– HRZE
• TDM for HIV drugs
– also TB drugs
TB-HIV “RIF”
![Page 15: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/15.jpg)
Case (continued)
![Page 16: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/16.jpg)
TB-HIV patients N=2:
“In addition to the use of DOT to ensure compliance, we advocate routine screening of antimycobacterial-drug levels in HIV-infected
patients with tuberculosis, particularly those with advanced HIV disease.”
N=287
“We believe this is an important area for continued investigation, particularly correlations of low body weight with both adverse drug
reactions and therapeutic drug levels of MDR-TB treatments.”
Patel et al NEJM 1995; Farley PlosOne 2011
Routine care today?
![Page 17: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/17.jpg)
time (hr)
0 2 4 6 8 10 12
Rifam
pic
in c
oncentr
ation (
mg/L
)
0
2
4
6
8
Which blood sample to take from my patient?
Rifampin Peak ≠ C2
![Page 18: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/18.jpg)
Methods of blood sampling
• Classical: trough/peak
• Full PK curve
• Optimized: – limited sampling
Time post dose
Seru
m c
once
ntr
ation
MIC
![Page 19: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/19.jpg)
Plasma and/or dried blood sample
• Dried blood spot – Convenient sampling – Sample stability – Whole blood instead of plasma – Advanced equipement
• Plasma
– Venous access
– Samples often instable
– ‘Relative simple’ equipement
![Page 20: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/20.jpg)
Dried blood spot sampling; clean
![Page 21: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/21.jpg)
Dried blood spot sampling; prick
![Page 22: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/22.jpg)
Dried blood spot sampling; wipe
![Page 23: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/23.jpg)
Dried blood spot; card
![Page 24: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/24.jpg)
Dried blood spot sampling; blood
![Page 25: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/25.jpg)
Dried blood spot sampling; spot
![Page 26: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/26.jpg)
Dried blood spot sampling
![Page 27: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/27.jpg)
Dried blood spot cards
Vu et al J Chrom B 2011
![Page 28: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/28.jpg)
TDM in programmatic TB treatment
• Populations at risk for low drug exposure
• Patients failing to respond to treatment
• M/XDR-TB
• Use limited sampling strategy
• Use DBS sampling
![Page 29: Treatment of Tuberculosis “Therapeutic Drug Monitoring” · routine screening of antimycobacterial-drug levels in HIV-infected patients with tuberculosis, particularly those with](https://reader035.fdocuments.us/reader035/viewer/2022081517/5ee1fd15ad6a402d666ca8e6/html5/thumbnails/29.jpg)
To summarize:
Patient
Characteristics
Protocol for
Programmatic TDM
Drug concentration
(AUC)
Response
to
treatment
WHO treatment
Drug
susceptibility
(MIC)